Yes. In addition, Aetna is waiving member cost-sharing for diagnostic testing related to COVID-19. The test can be done by any authorized testing facility. This member cost-sharing waiver applies to all Commercial, Medicare and Medicaid lines of business. The policy aligns with the Families First and CARES legislation and regulations requiring all health plans to provide coverage of COVID-19 testing without cost share. The requirement also applies to self-insured plans. Per guidance from the Centers for Medicare & Medicaid Services (CMS), the Department of Labor and the Department of the Treasury, all Commercial, Medicaid and Medicare plans must cover COVID-19 serological (antibody) testing with no cost-sharing.

Aetna will cover, without cost share, diagnostic (molecular PCR or antigen) tests to determine the need for member treatment.¹ This includes to direct-to-consumer/home-based diagnostic or antigen tests. Aetna’s health plans generally do not cover a test performed at the direction of a member’s employer in order to obtain or maintain employment or to perform the member’s normal work functions or for return to school or recreational activities, except as required by applicable law.

Aetna will cover, without cost share, serological (antibody) tests that are ordered by a physician or authorized health care professional and are medically necessary. Aetna’s health plans do not cover serological (antibody) tests that are for purposes of: return to work or school or for general health surveillance or self-surveillance or self-diagnosis, except as required by applicable law. Refer to the CDC website for the most recent guidance on antibody testing.

This policy for diagnostic and antibody testing applies to Commercial, Medicare and Medicaid plans.²

¹Aetna will follow all federal and state mandates for insured plans, as required.

²Regulations regarding testing for Aetna Medicaid members vary by state and, in some cases, may change in light of the current situation. Providers are encouraged to call their provider services representative for additional information.

Yes. Prior to COVID-19, testing for infectious diseases were included in the rate for surgical procedures and that policy will continue during the COVID-19 pandemic.

Yes. If the plan provides in and out of network coverage, then the cost-sharing waiver applies to testing performed or ordered by in-network or out-of-network providers. The policy aligns with Families First and CARES Act legislation and regulations requiring all health plans to provide coverage of COVID-19 testing without cost share.

Aetna follows FDA guidelines and other applicable regulations regarding the ordering of a test. An order can often take place as part of being tested at a COVID-19 drive-through test site or purchasing a direct-to-consumer/home-based test.

In effort to expand testing capabilities, U.S. Department of Health & Human Services (DHS) authorized pharmacists to order and administer COVID-19 tests, including serology tests, that the FDA has authorized. Pharmacists, in partnership with other health care providers, are well positioned to aid COVID-19 testing expansion.

Routine testing for influenza, strep, and other respiratory infections without a COVID-19 test will be covered subject to applicable cost sharing under the member’s plan.

We cover, without member cost sharing, a same day office, emergency room, or other provider visit at which a COVID-19 test is ordered or administered. If as part of that visit the provider administers or orders a test for influenza, strep, or other respiratory infection, that additional testing will also be covered without member cost sharing.

Tests must be FDA authorized in accordance with the requirements of the CARES Act.

Commercial labs are in the process of updating their provider community about their capabilities and how to order tests. National labs will not collect specimens for COVID-19 testing. Instead, an appropriate specimen should be collected at the health care facility where the patient was seen and the test was ordered or at other non-lab facilities. The specimen should be sent to these laboratories using standard procedures.

Aetna is reaching out to the commercial labs about their ability to provide the COVID-19 testing. The following are some of the national labs approved to do COVID-19 testing(other commercial labs are also approved):

To ensure access for COVID-19 testing and have consistent reimbursement, Aetna will reimburse contracted and non-contracted providers for COVID-19 testing as follows in accordance with the member’s benefit plan³. The following rates are used for COVID-19 testing for commercial and Medicare plans, unless noted otherwise:

Diagnostic testing/handling rates - Medicare

• HCPCS U0001: $35.92 per test
• HCPCS U0002: $51.31 per test
• HCPCS U0003: $100 per test (Commercial plans only)
• HCPCS U0003: $75 per test (Medicare plans only)
• HCPCS U0004: $100 per test (Commercial plans only)
• HCPCS U0004: $75 per test (Medicare plans only)
• HCPCS U0005: $25 per test (Medicare plans only)*
• CPT 0202U: $416.78 per test
• CPT 0223U: $416.78 per test
• CPT 0225U: $416.78 per test
• CPT 0226U: $42.28 per test
• CPT 0240U: $142.63 per test
• CPT 0241U: $142.63 per test
• CPT 86413: $42.13 per test
• CPT 87426: $45.23 per test
• CPT 87635: $51.31 per test
• CPT 87636: $142.63 per test
• CPT 87637: $142.63 per test
• CPT 87811: $41.38 per test
• CPT 99000: $7 per test
• CPT 99001: $13 per test
• CPT G2023: $23.46
• CPT G2034: $25.46

Antibody testing rates - Medicare

• CPT 86328: $45.23 per test
• CPT 86408: $42.13 per test
• CPT 86409: $105.33 per test
• CPT 86769: $42.13 per test
• CPT 0224U: $42.13 per test

These reimbursement rates for COVID-19 diagnostic and antibody testing are based on rates announced by CMS. For more information and future updates, visit the CMS website and its newsroom. By submitting a claim to Aetna for COVID-19 testing, providers acknowledge that the above amounts will be accepted as payment in full for each COVID-19 test performed, and that they will not seek additional reimbursement from members.

*As announced by CMS, starting January 1, 2021, Medicare will make an additional $25 add-on payment to laboratories for a COVID-19 diagnostic test run on high throughput technology if the laboratory: a) completes the test in two calendar days or less, and b) completes the majority of their COVID-19 diagnostic tests that use high throughput technology in two calendar days or less for all of their patients (not just their Medicare patients) in the previous month. Laboratories that complete a majority of COVID-19 diagnostic tests run on high throughput technology within two days will be paid $100 per test by Medicare, while laboratories that take longer will receive $75 per test. CMS established these requirements to support faster high throughput COVID-19 diagnostic testing and to ensure all patients (not just Medicare patients) benefit from faster testing. These actions will be implemented under the amended Administrative Ruling (CMS-2020-1-R2) and coding instructions for the $25 add-on payment (HCPCS code U0005).

Learn more about CMS Changes Medicare Payment to Support Faster COVID-19 Diagnostic Testing or for additional information and future updates, visit the CMS newsroom.

³Rates above are not applicable to Aetna Better Health Plans. Aetna Better Health plan pricing may be determined by each individual health plan in accordance with its state contracts.

Aetna generally does not reimburse doctors and dentists for Personal Protection Equipment. PPE, like other disposable infection control supplies, is part of the cost of the underlying procedure.

CVS Health is uniquely positioned to play a vital role in supporting local communities and the overall health care system in addressing the COVID-19 pandemic. Our ability to coordinate the availability of COVID-19 testing bolsters states’ efforts to manage the spread of the virus.

In March, CVS Health opened a pilot drive-through COVID-19 test site in a parking lot at a CVS Pharmacy store in Shrewsbury, MA. This pilot provided the company with a number of key learnings, which helped inform the company’s ability to improve on and maximize drive-through testing for consumers.

In April, CVS Health joined forces with the U. S. Department of Health and Human Services and state governments in Connecticut, Georgia, Massachusetts, Michigan and Rhode Island to help increase access to rapid COVID-19 testing at large-scale sites in publicly accessible areas. Each site operated seven days a week, providing results to patients on-site, through the end of June.

Since then, CVS Health has continued to expand access to COVID-19 testing, establishing testing sites at more than 4,800 CVS Pharmacy locations across the country, including nearly 1,000 of which provide rapid-results testing.

For more information on test site locations in a specific state visit CVS COVID-19: Testing locations.

Our pharmacies and MinuteClinics are uniquely positioned to help address the pandemic and protect people’s health. Building on the company’s comprehensive efforts to help slow the spread of the virus, we can bring safe and effective testing options closer to home and help increase access to testing options for even more individuals. This allows us to continue to help slow the spread of the virus.

Testing will not be available at all CVS Pharmacy locations. CVS Pharmacy, HealthHUB^® and MinuteClinic^® will continue to serve customers and patients.

CVS Health currently has more than 4,800 drive –thru testing locations across the country offering COVID-19 testing. Through this effort we are hoping to provide access in areas of the country that need additional testing and are selecting CVS Pharmacy locations with this criteria in mind.

Based on the availability of supplies and lab capacity, each site can test between 20 to 50 tests per day.

Yes, patients must register in advance at CVS MinuteClinic to schedule an appointment. Patients will need to pre-register, provide their insurance information as appropriate and verify their eligibility for testing. Once they have registered, the patient will be provided with an appointment window for that same day or up to two days out.

Yes, first responders and health care workers will be able to sign up if their local or state health departments have prioritized these groups for testing, if they have a physician’s referral, or if they are symptomatic.

Aetna will waive member cost-sharing for inpatient admissions for treatment of COVID-19 or health complications associated with COVID-19. This policy applies to all Aetna-insured commercial plans and is effective immediately for any such admission through February 28, 2021. Self-insured plan sponsors offer this waiver at their discretion.

Yes, Aetna will cover the cost for treatment of COVID-19 for our Medicare Advantage members in full in the provider office. We will also cover the cost of the hospital stay for all our Medicare Advantage members admitted March 25, 2020 through February 28, 2021.

Regulations regarding cost-sharing for Medicaid beneficiaries vary by state and continue to evolve in light of the current situation. We have suspended cost-sharing requirements, including premiums and copays, for adults and children covered by Medicaid and CHIP, in those states where permitted to do so by the appropriate regulators.

All claims received for Aetna-insured members going forward will be processed based on this new policy. If in-patient treatment was required for a member with a positive COVID-19 diagnosis prior to this announcement it will be processed in accordance with this new policy. In the event a claim has already been processed prior to this policy going into effect, members should contact Customer Service so the claim can be reprocessed accordingly.

No, Aetna will pay the amount of the cost-sharing the member would have ordinarily paid so the provider would receive the same total payment.

Yes. During the COVID-19 pandemic, Aetna will pay for emergency care at the in-network level regardless of the location.